Development of Anthraquinone Analogues as Phosphoglycerate Mutase 1 Inhibitors

Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry
Ke HuangLu Zhou

Abstract

Phosphoglycerate mutase 1 (PGAM1) coordinates glycolysis and biosynthesis to promote cancer cell proliferation, and is believed to be a promising target for cancer therapy. Herein, based on the anthraquinone scaffold, we synthesized 31 anthraquinone derivatives and investigated the structure-activity relationship (SAR). The 3-substitient of sulfonamide on the anthraquinone scaffold was essential for maintaining potency and the modifications of the hydroxyl of alizarin would cause a sharp decrease in potency. In the meantime, we determined the co-crystal structure of PGAM1 and one of the anthraquinone inhibitors 9i with IC50 value of 0.27 μM. The co-crystal structure revealed that F22, K100 and R116 of PGAM1 were critical residues for the binding of inhibitors which further validated the SAR. Consistent with the crystal structure, a competitive assay illustrated that compound 9i was a noncompetitive inhibitor. In addition, compound 9i effectively restrained different lung cancer cells proliferation in vitro. Taken together, this work provides reliable guide for future development of PGAM1 inhibitors and compound 9i may act as a new leading compound for further optimization.

References

Sep 1, 1979·Journal of Medicinal Chemistry·K C MurdockR V Citarella
Apr 18, 2002·Proceedings of the National Academy of Sciences of the United States of America·Christopher A HunterCristiano Zonta
Feb 24, 1956·Science·O WARBURG
Dec 2, 2004·Acta Crystallographica. Section D, Biological Crystallography·Paul Emsley, Kevin Cowtan
Oct 4, 2005·Nature Biotechnology·Michael J EvansBenjamin F Cravatt
Oct 6, 2006·Medicinal Research Reviews·Qing HuangChoon Nam Ong
Jun 16, 2007·Journal of Cellular Biochemistry·Joel B BerletchTrygve O Tollefsbol
Jan 8, 2008·Cell Metabolism·Ralph J DeBerardinisCraig B Thompson
Jun 10, 2008·Cancer Cell·Guido Kroemer, Jacques Pouyssegur
May 23, 2009·Science·Matthew G Vander HeidenCraig B Thompson
Aug 17, 2010·Chemical Research in Toxicology·Fei LiZijian Wang
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Apr 5, 2011·Acta Crystallographica. Section D, Biological Crystallography·Martyn D WinnKeith S Wilson
Sep 1, 2011·Nature Reviews. Drug Discovery·Matthew G Vander Heiden
Feb 14, 2012·ACS Combinatorial Science·Marina Y FossoCheng-Wei Tom Chang
May 3, 2012·Genes & Development·Chi V Dang
Sep 27, 2012·Cancer Discovery·Jason R Cantor, David M Sabatini
Nov 16, 2012·Nature·Almut Schulze, Adrian L Harris
Nov 17, 2012·Cancer Cell·Barbara Chaneton, Eyal Gottlieb
Nov 23, 2015·Molecular Cell·Gina M DeNicola, Lewis C Cantley
Jan 16, 2016·Cell Metabolism·Natalya N Pavlova, Craig B Thompson
Apr 26, 2016·Medicinal Research Reviews·Enas M Malik, Christa E Müller
Jan 1, 1997·Methods in Enzymology·Zbyszek Otwinowski, Wladek Minor
Feb 12, 2017·Cell·Matthew G Vander Heiden, Ralph J DeBerardinis
Jun 15, 2017·Frontiers in Pharmacology·Xiaoguang LiJian Ding
Dec 13, 2017·Trends in Cell Biology·Adam J Wolpaw, Chi V Dang

❮ Previous
Next ❯

Methods Mentioned

BETA
amidation
X-ray

Software Mentioned

Pymol
eLBOW
COOT
CCP4
Phenix

Related Concepts

Related Feeds

Cancer Metabolism: Therapeutic Targets

Targeting the mechanisms by which cancer cells acquire energy for metabolic needs is a therapeutic target. Discover the latest research on cancer metabolism and therapeutic targets.